Goldman Sachs Group Inc. Has $112,000 Stock Holdings in MBX Biosciences, Inc. $MBX

Goldman Sachs Group Inc. cut its stake in shares of MBX Biosciences, Inc. (NYSE:MBX) by 56.4% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 15,168 shares of the company’s stock after selling 19,659 shares during the period. Goldman Sachs Group Inc.’s holdings in MBX Biosciences were worth $112,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Woodline Partners LP boosted its position in MBX Biosciences by 44.1% during the first quarter. Woodline Partners LP now owns 877,461 shares of the company’s stock valued at $6,476,000 after purchasing an additional 268,740 shares during the last quarter. Parkman Healthcare Partners LLC boosted its position in MBX Biosciences by 93.1% during the first quarter. Parkman Healthcare Partners LLC now owns 328,323 shares of the company’s stock valued at $2,423,000 after purchasing an additional 158,323 shares during the last quarter. Jump Financial LLC acquired a new position in MBX Biosciences during the first quarter valued at approximately $214,000. Walleye Capital LLC acquired a new stake in shares of MBX Biosciences in the first quarter valued at approximately $240,000. Finally, Exome Asset Management LLC acquired a new stake in shares of MBX Biosciences in the first quarter valued at approximately $982,000.

MBX Biosciences Trading Up 2.5%

NYSE:MBX opened at $17.94 on Tuesday. The stock has a market cap of $602.68 million and a P/E ratio of -3.95. The stock has a 50 day simple moving average of $13.53 and a 200 day simple moving average of $11.38. MBX Biosciences, Inc. has a 1-year low of $4.81 and a 1-year high of $27.50.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on MBX. Citigroup reaffirmed an “outperform” rating on shares of MBX Biosciences in a research report on Monday, September 22nd. Oppenheimer began coverage on MBX Biosciences in a research report on Wednesday, July 16th. They issued an “outperform” rating and a $38.00 price objective for the company. Finally, Mizuho raised their price objective on MBX Biosciences from $38.00 to $56.00 and gave the company an “outperform” rating in a research report on Wednesday, September 24th. Nine equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $39.88.

About MBX Biosciences

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.